{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:50:54Z","timestamp":1787316654896,"version":"build-2736575974"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"vor","delay-in-days":550,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.exphem.2022.12.001","type":"journal-article","created":{"date-parts":[[2022,12,11]],"date-time":"2022-12-11T01:22:59Z","timestamp":1670721779000},"page":"3-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Assessing the frequency of CD163+ tumor-associated macrophages and CD3+ T lymphocytes between MGUS and plasma cell myeloma"],"prefix":"10.1016","volume":"119-120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9454-2692","authenticated-orcid":false,"given":"Aaron","family":"Niblock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Rajendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Laverty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-1947","authenticated-orcid":false,"given":"Philip","family":"Logue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Denis","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2022.12.001_bib0001","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0950-3536(05)80255-0","article-title":"Plasma cell dyscrasias: classification, clinical and laboratory characteristics, and differential diagnosis","volume":"8","author":"Boccadoro","year":"1995","journal-title":"Baillieres Clin Haematol"},{"key":"10.1016\/j.exphem.2022.12.001_bib0002","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4065\/mcp.2010.0520","article-title":"Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence","volume":"85","author":"Rajkumar","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.exphem.2022.12.001_bib0003","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"Along-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.12.001_bib0004","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1182\/blood.V40.5.719.719","article-title":"Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma","volume":"40","author":"Kyle","year":"1972","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.12.001_bib0005","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.12.001_bib0006","unstructured":"Cancer Research UK. Myeloma statistics. Available at:https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/myeloma. Accessed July 15, 2021."},{"key":"10.1016\/j.exphem.2022.12.001_bib0007","doi-asserted-by":"crossref","first-page":"806","DOI":"10.2174\/1568009617666170214102301","article-title":"Multiple myeloma and the immune microenvironment","volume":"17","author":"Kawano","year":"2017","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.exphem.2022.12.001_bib0008","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood.2019846782","article-title":"Monoclonal gammopathy of undetermined significance","volume":"133","author":"Mouhieddine","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.12.001_bib0009","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1053\/j.seminhematol.2010.11.004","article-title":"Myelomagenesis: capturing early microenvironment changes","volume":"48","author":"Korde","year":"2011","journal-title":"Semin Hematol"},{"key":"10.1016\/j.exphem.2022.12.001_bib0010","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.3390\/cancers12082274","article-title":"Mechanisms of T-cell exhaustion in pancreatic cancer","volume":"12","author":"Saka","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.exphem.2022.12.001_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3960\/jslrt.56.1","article-title":"Follicular lymphoma: the role of the tumor microenvironment in prognosis","volume":"56","author":"Sugimoto","year":"2016","journal-title":"J Clin Exp Hematop"},{"key":"10.1016\/j.exphem.2022.12.001_bib0012","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.2147\/CMAR.S199832","article-title":"M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer","volume":"11","author":"Cao","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.exphem.2022.12.001_bib0013","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1189\/jlb.0609385","article-title":"Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation","volume":"86","author":"Solinas","year":"2009","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.exphem.2022.12.001_bib0014","unstructured":"Frauenfeld L, Sch\u00fcrch CM. Statins & CD markers. CD3. Available at: https:\/\/www.pathologyoutlines.com\/topic\/cdmarkerscd3.html. Accessed August 11, 2021."},{"key":"10.1016\/j.exphem.2022.12.001_bib0015","unstructured":"Caraccio C, Bruehl F. Statins & CD markers. CD68. Available at:https:\/\/www.pathologyoutlines.com\/topic\/cdmarkerscd68.html. Accessed August 11, 2021."},{"key":"10.1016\/j.exphem.2022.12.001_bib0016","unstructured":"Pernick N. Statins & CD markers. CD160-169. Available at: https:\/\/www.pathologyoutlines.com\/topic\/cdmarkerscd160.html. Accessed August 11, 2021."},{"key":"10.1016\/j.exphem.2022.12.001_bib0017","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jaci.2020.02.034","article-title":"CD163 expression defines specific, IRF8-dependent, immune-modulatory macrophages in the bone marrow","volume":"146","author":"Fischer-Riepe","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.exphem.2022.12.001_bib0018","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.7150\/jca.30102","article-title":"High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens","volume":"10","author":"Wang","year":"2019","journal-title":"J Cancer"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X22008359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X22008359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:38:05Z","timestamp":1759567085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X22008359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":18,"alternative-id":["S0301472X22008359"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2022.12.001","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the frequency of CD163+ tumor-associated macrophages and CD3+ T lymphocytes between MGUS and plasma cell myeloma","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2022.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier Inc. on behalf of ISEH \u2013 Society for Hematology and Stem Cells.","name":"copyright","label":"Copyright"}]}}